The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections
Abstract
Objective: This article critically evaluates common Pseudomonas aeruginosa resistance mechanisms and the properties newer β-lactam antimicrobials possess to evade these mechanisms. Data Sources: An extensive PubMed, Google Scholar, and ClinicalTrials.gov search was conducted (January 1995 to July 2020) to identify relevant literature on epidemiology, resistance mechanisms, antipseudomonal agents, newer β-lactam agents, and clinical data available pertaining to P aeruginosa. Study Selection and Data Extraction: Relevant published articles and package inserts were reviewed for inclusion. Data Synthesis: Therapeutic options to treat P aeruginosa infections are limited because of its intrinsic and acquired resistance mechanisms. The goal was to identify advances with newer β-lactams and characterize improvements in therapeutic potential for P aeruginosa infections. Relevance to Patient Care and Clinical Practice: Multidrug-resistant (MDR) P aeruginosa isolates are increasingly encountered from a variety of infections. This review highlights potential activity gains of newer β-lactam antibacterial drugs and the current clinical data to support their use. Pharmacists will be asked to recommend or evaluate the use of these agents and need to be aware of information specific to P aeruginosa, which differs from experience derived from Enterobacterales infections. Conclusions: Newer agents, including ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam, and cefiderocol, are useful for the treatment of MDR P aeruginosa infections. These agents offer improved efficacy and less toxicity compared with aminoglycosides and polymyxins and can be used for pathogens that are resistant to first-line antipseudomonal β-lactams. Selection of one agent over another should consider availability, turnaround of susceptibility testing, and product cost. Efficacy data specific for pseudomonal infections are limited, and there are no direct comparisons between the newer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“treatments of P. aeruginosa infection are extremely difficult due to its rapid mutations and adaptation to gain resistance to antibiotics.6”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Function of Pseudomonas Porins in Uptake and Efflux
Hancock, R. E. W., & Brinkman, F. S. L. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160310 · Cited by 319
Research works printed but not linked: 66
- 10.2165/00003495-200767030-00003 · DOI · Paper page
- 10.1128/CMR.00040-09 · DOI · Paper page
- 10.1128/AAC.01587-18 · DOI
- 10.1002/14651858.CD003344.pub3 · DOI · Paper page
- 10.1128/JCM.02072-18 · DOI
- 10.1128/JCM.00203-19 · DOI · Paper page
- 10.3390/antibiotics9040189 · DOI
- 10.1592/phco.27.11.1490 · DOI
- 10.1093/cid/ciz1159 · doi:10.1093/cid/ciz1159
- 10.1128/AAC.00296-11 · DOI · Paper page
- 10.1007/s10123-018-0030-1 · doi:10.1007/s10123-018-0030-1
- 10.1128/AAC.03098-15 · DOI · Paper page
- 10.1021/ar300327a · DOI
- 10.1093/femsre/fux020 · DOI · Paper page
- 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
- 10.1111/j.1348-0421.1995.tb02193.x · DOI
- Naenna P, 2010, Southeast Asian J Trop Med Public Health, 41, 614
- 10.1016/j.ijmm.2011.10.001 · DOI · Paper page
- 10.1016/j.bjid.2016.10.008 · DOI
- 10.1128/aac.44.12.3322-3327.2000 · DOI · Paper page
- 10.1007/s10156-002-0193-7 · DOI
- 10.1099/jmm.0.001106 · DOI
- 10.3855/jidc.9486 · doi:10.3855/jidc.9486
- 10.1128/AAC.03057-14 · DOI · Paper page
- 10.1128/AAC.03681-14. · DOI
- 10.1128/AAC.03681-14 · DOI
- 10.1128/AAC.06064-11 · DOI
- 10.1128/AAC.04238-14 · DOI
- 10.1016/j.ijantimicag.2018.07.027 · doi:10.1016/j.ijantimicag.2018.07.027
- 10.1093/jac/dky204 · DOI
- 10.1093/ofid/ofz522 · DOI
- 10.1007/s40265-013-0168-2 · DOI · Paper page
- 10.1371/journal.pone.0180121 · doi:10.1371/journal.pone.0180121
- 10.1128/AAC.01737-10 · DOI
- 10.1128/AAC.01590-12 · DOI
- 10.1128/AAC.02462-13 · DOI · Paper page
- 10.1016/j.jgar.2020.04.017 · DOI
- 10.1093/ofid/ofy280 · DOI
- 10.1128/AAC.02291-19 · DOI
- 10.1093/cid/ciz816 · DOI · Paper page
- 10.1128/AAC.03074-15 · doi:10.1128/aac.03074-15
- 10.1016/S1473-3099(19)30403-7 · DOI · Paper page
- 10.1016/S0140-6736(14)62220-0 · DOI · Paper page
- 10.1128/AAC.01443-17 · DOI · Paper page
- 10.1001/jama.2018.0438 · DOI · Paper page
- 10.1007/s40121-018-0214-1 · DOI · Paper page
- 10.1128/AAC.00513-10 · DOI
- 10.1128/AAC.00513-10 · DOI
- 10.1128/AAC.00843-15 · DOI
- 10.1007/s40121-018-0214-1 · DOI · Paper page
- 10.1128/AAC.00633-16 · DOI · Paper page
- 10.1002/phar.2378 · DOI
- 10.1128/AAC.00830-15 · DOI · Paper page
- 10.1007/s40265-017-0851-9 · DOI · Paper page
- 10.2217/fmb-2018-0054 · DOI
- 10.1093/cid/ciaa381 · DOI
- 10.1016/j.diagmicrobio.2019.05.001 · DOI
- 10.1093/jac/dkx139 · DOI · Paper page
- 10.1093/cid/ciz530 · DOI · Paper page
- 10.1111/nyas.12024 · DOI
- 10.1128/AAC.02531-16 · DOI
- 10.1016/j.ijantimicag.2018.11.007 · DOI
- 10.1128/AAC.01454-17 · DOI · Paper page
- 10.1016/S1473-3099(18)30554-1 · DOI · Paper page
- 10.2147/IDR.S225553 · DOI
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Dulin D, Clancy CJ. Infectious Disease Society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections. A focus on extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenemresistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR- P aeruginosa ). Accessed October 17, 2020. https://www.idsociety.org/globalassets/idsa/practice-guidelines/amr-guidance/idsa-amr-guidance.pdf · DOI · Paper page
Cited by
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Metadata
- Authors
- Blomquist, K. C., & Nix, D. E.
- Affiliations
- Department of Pharmacy Practice & Science, University of Arizona, Tucson, Arizona, USA
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2020-11-23
- Volume
- 55
- Issue
- 8
- Pages
- 1010-1024
- ISSN
- 1060-0280
- 1542-6270
- Cited by
- 45
- References
- 2
- Language
- en
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.